Denali Therapeutics Inc. Other Noncash Income (Expense)
Denali Therapeutics Inc. (DNLI) reported Other Noncash Income (Expense) of $223.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OtherNoncashIncomeExpense · last filed 2026-08-06
- Denali Therapeutics Inc. other noncash income (expense) for the quarter ending 2026-06-30 was $517.00K.
- Denali Therapeutics Inc. other noncash income (expense) for the quarter ending 2026-03-31 was -$294.00K.
- Denali Therapeutics Inc. other noncash income (expense) for the quarter ending 2025-06-30 was $0.00.
- Denali Therapeutics Inc. other noncash income (expense) for the quarter ending 2025-03-31 was $0.00.
- Denali Therapeutics Inc. other noncash income (expense) for fiscal 2025 was -$49.00K.
- Denali Therapeutics Inc. other noncash income (expense) for fiscal 2024 was $0.00.
- Denali Therapeutics Inc. other noncash income (expense) for fiscal 2023 was -$2.00K.
- Denali Therapeutics Inc. other noncash income (expense) for fiscal 2022 was -$63.00K.
| Period end | Other Noncash Income (Expense) 3 month | Other Noncash Income (Expense) 6 month | Other Noncash Income (Expense) 9 month | Other Noncash Income (Expense) 12 month |
|---|---|---|---|---|
| 2026-06-30 | $517.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $223.00K 10-Q · filed 2026-08-06 | ||
| 2026-03-31 | -$294.00K 10-Q · filed 2026-05-07 | |||
| 2025-12-31 | -$49.00K 10-K · filed 2026-02-26 | |||
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $0.00 10-Q · filed 2026-08-06 | ||
| 2025-03-31 | $0.00 10-Q · filed 2026-05-07 | |||
| 2024-12-31 | $0.00 10-K · filed 2026-02-26 | |||
| 2023-12-31 | -$2.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$2.00K derived: sum of 2 quarters · filed 2026-02-26 | -$2.00K 10-K · filed 2026-02-26 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $0.00 10-Q · filed 2023-11-07 | ||
| 2023-06-30 | $0.00 10-Q · filed 2023-08-08 | |||
| 2022-12-31 | -$12.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$58.00K derived: sum of 2 quarters · filed 2025-02-27 | -$63.00K derived: sum of 3 quarters · filed 2025-02-27 | -$63.00K 10-K · filed 2025-02-27 |
| 2022-09-30 | -$46.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | -$51.00K derived: sum of 2 quarters · filed 2023-11-07 | -$51.00K 10-Q · filed 2023-11-07 | -$51.00K derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | -$5.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | -$5.00K 10-Q · filed 2023-08-08 | -$5.00K derived: sum of 3 quarters · filed 2024-02-28 | -$5.00K derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | $0.00 10-Q · filed 2022-05-05 | $0.00 derived: sum of 2 quarters · filed 2024-02-28 | $0.00 derived: sum of 3 quarters · filed 2024-02-28 | -$2.00K derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $0.00 derived: sum of 2 quarters · filed 2024-02-28 | -$2.00K derived: sum of 3 quarters · filed 2024-02-28 | $0.00 10-K · filed 2024-02-28 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | -$2.00K derived: sum of 2 quarters · filed 2022-11-03 | $0.00 10-Q · filed 2022-11-03 | -$20.00K derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-06-30 | -$2.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $0.00 10-Q · filed 2022-08-08 | -$20.00K derived: sum of 3 quarters · filed 2023-02-27 | -$77.00K derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-03-31 | $2.00K 10-Q · filed 2022-05-05 | -$18.00K derived: sum of 2 quarters · filed 2023-02-27 | -$75.00K derived: sum of 3 quarters · filed 2023-02-27 | -$89.00K derived: sum of 4 quarters · filed 2023-02-27 |
| 2020-12-31 | -$20.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | -$77.00K derived: sum of 2 quarters · filed 2023-02-27 | -$91.00K derived: sum of 3 quarters · filed 2023-02-27 | -$38.00K 10-K · filed 2023-02-27 |
| 2020-09-30 | -$57.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | -$71.00K derived: sum of 2 quarters · filed 2021-11-04 | -$18.00K 10-Q · filed 2021-11-04 | -$94.00K derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | -$14.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | $39.00K 10-Q · filed 2021-08-04 | -$37.00K derived: sum of 3 quarters · filed 2022-02-28 | $77.00K derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | $53.00K 10-Q · filed 2021-05-05 | -$23.00K derived: sum of 2 quarters · filed 2022-02-28 | $91.00K derived: sum of 3 quarters · filed 2022-02-28 | $404.00K derived: sum of 4 quarters · filed 2022-02-28 |
| 2019-12-31 | -$76.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $38.00K derived: sum of 2 quarters · filed 2022-02-28 | $351.00K derived: sum of 3 quarters · filed 2022-02-28 | $351.00K 10-K · filed 2022-02-28 |
| 2019-09-30 | $114.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $427.00K derived: sum of 2 quarters · filed 2020-11-05 | $427.00K 10-Q · filed 2020-11-05 | $463.00K derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-06-30 | $313.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-07 | $313.00K 10-Q · filed 2020-08-07 | $349.00K derived: sum of 3 quarters · filed 2021-02-26 | $349.00K derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-03-31 | $0.00 10-Q · filed 2020-05-07 | $36.00K derived: sum of 2 quarters · filed 2021-02-26 | $36.00K derived: sum of 3 quarters · filed 2021-02-26 | |
| 2018-12-31 | $36.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26 | $36.00K derived: sum of 2 quarters · filed 2021-02-26 | $36.00K 10-K · filed 2021-02-26 | |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | $0.00 10-Q · filed 2019-11-06 | ||
| 2018-06-30 | $0.00 10-Q · filed 2019-08-06 | |||
| 2017-12-31 | -$1.00K 10-K · filed 2020-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |